Multiple Sclerosis (MS) (cont.)
Tremlett H, et al. (2010). New perspectives in the natural history of multiple sclerosis. Neurology, 74(24): 2004–2015.
Ropper AH, Samuels MA (2009). Multiple sclerosis and allied demyelinative diseases. In Adams and Victor's Principles of Neurology, 9th ed., pp. 874–903. New York: McGraw-Hill.
National Clinical Advisory Board of the National Multiple Sclerosis Society (2008). Disease Management Consensus Statement. New York: National Multiple Sclerosis Society. Available online: http://www.nationalmssociety.org/for-professionals/healthcare-professionals/publications/expert-opinion-papers/index.aspx.
Burt RK, et al. (2009). Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. Lancet Neurology, 8(3): 244–253.
Fassas A, et al. (2011). Long-term results of stem cell transplantation for MS: A single-center experience. Neurology, 76(12): 1066–1070.
Other Works Consulted
Burton JM, et al. (2009). Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database of Systematic Reviews (3).
Cortese I, et al. (2011). Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 76(3): 294–300.
Courtney AM, et al. (2009). Multiple sclerosis. Medical Clinics of North America, 93(2): 451–476.
Fox RJ, Arnold DL (2009). Seeing injectable MS therapies differently: They are more similar than different. Neurology, 72(23): 1972–1973.
Giesser B (2010). Reproductive Issues in Persons With Multiple Sclerosis. Clinical Bulletin: Information Health Professionals. Available online: http://www.nationalmssociety.org/for-professionals/healthcare-professionals/publications/clinical-bulletins/index.aspx.
Goodin DS, et al. (2008, reaffirmed 2010). Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 68(13): 977–984.
Grossman P, et al. (2010). MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial. Neurology, 75(13): 1141–1149.
Kelly VM, et al. (2009). Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology, 73(22): 1831–1836.
Marriott JJ, et al. (2010). Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 74(18): 1463–1470.
McDonald WI, et al. (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology, 50(1): 121–127.
Polman CH, et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Annals of Neurology, 58(6): 840–846.
Polman CH, et al. (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine, 354(9): 899–910.
Polman CH, et al. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69(2): 292–302.
Yousry TA, et al. (2006). Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New England Journal of Medicine, 354(9): 924–933.
eMedicineHealth Medical Reference from Healthwise
To learn more visit Healthwise.org
© 1995-2012 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.